Critical Denial RiskRevenue at Risk: $1.0M–$2.1M (est)Published Aug 2025 · Pilot Live Jan 2026

Prior Auth Tightening Increases Inpatient Denial Exposure

CMS launched the Wasteful and Inappropriate Services Reduction (WISeR) Model on January 1, 2026 in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. It is the first widespread use of prior authorization in Traditional Medicare, routing ~17 outpatient service categories through contractor-operated AI screening with financial incentives tied to denial rates.

Affected Payers

· Medicare FFS (Traditional Medicare)
· Medicare Advantage
· Commercial

Service Lines

· Prior Auth
· Medical Necessity
· Procedure Auth
· Experimental

01 — Signal

Why PAULA flagged this

Directly affects prior-auth denial risk scoring: API-based PA decisions and shortened response windows reduce silent denials but raise documentation-completeness thresholds CLIP must validate pre-submission. Traditional Medicare has historically carried near-zero PA burden — WISeR inverts that posture overnight in six states.

Recommended Action — This Week

UR team must implement a WISeR-specific PA checklist for all Q4100–Q4299 submissions in the six pilot states, requiring wound photo documentation, cm² measurements at minimum two prior visits, explicit MD attestation of standard care failure with dates, and ICD-10 wound etiology mapped to product selection rationale.

Locked · Full Brief

Scenarios, defenses, P2P scripts, executive lenses, and payer impact are available with the full brief.

02 — Full Analysis

What WISeR changes

WISeR uses outside contractor companies employing AI tools to process prior authorizations for approximately 17 specific outpatient services — including skin and tissue substitutes, electrical nerve-stimulator implants, and knee arthroscopy for knee osteoarthritis.

Key features: (1) Final decisions are made by licensed clinicians, not machines; (2) Contractors are paid based on their ability to reduce unnecessary services and lower spending — creating financial incentives to deny care; (3) Critics note that similar payment-for-denials models generated denial rates up to 16× higher than typical per the PSI report; (4) Patient advocates have raised alarm about erosion of Traditional Medicare's historic lack of PA; (5) Congressional legislation was introduced to prevent similar models from expanding.

03 — Denial Scenarios PAULA is Watching

Three high-probability denial patterns

PAULA inference based on payer behavior patterns and the source rule's structure — not directly quoted in the regulatory text. Verify against current payer policy before citing in an appeal.

Scenario · 01

Skin and Tissue Substitute Claim Denied for Missing Wound Severity Documentation

Payer Argument

WISeR contractor argues that the pre-service PA submission for a skin/tissue substitute (e.g., HCPCS Q4186 or similar Q4100–Q4299 range product) lacks wound measurement documentation, wound chronicity evidence, and documented failure of standard wound care. Contractor AI flags the incomplete submission; licensed clinician upholds denial citing insufficient medical necessity. Contractor's financial incentive to reduce approvals amplifies likelihood of denial on marginal submissions.

Defense

UR team must implement a WISeR-specific PA checklist for all Q4100–Q4299 submissions: wound photo documentation, cm² measurements at minimum two prior visits, explicit MD attestation of standard care failure with dates, and ICD-10 wound etiology mapped to product selection rationale. CLIP should block PA submission if any of these fields are absent in the EHR pre-submission note. Physician advisor must co-sign the PA attestation block, not delegate to mid-level.

P2P Framing

Per WISeR model documentation requirements as published by CMMI, final authorization decisions must be made by a licensed clinician. Our submission includes wound measurements, treatment duration, ICD-10 code, and product rationale satisfying the medical necessity standard for skin and tissue substitutes under CMS LCD policy. The contractor's AI-flagged deficiency was a formatting gap, not a clinical insufficiency. I ask that the reviewing clinician evaluate the full clinical record, not only the structured submission fields.

Scenario · 02

Electrical Nerve Stimulator Implant PA Denied for Inadequate Conservative Treatment Trial Documentation

Payer Argument

WISeR contractor denies PA for spinal cord stimulator or peripheral nerve stimulator implant (CPT 64565, 64575, or 64580) arguing the submitted documentation does not demonstrate an adequate trial of conservative pain management prior to implantation. Contractor licensed clinician upholds AI-flagged denial, citing absence of a documented structured pain management trial with specific modalities, duration, and response outcomes. Financial incentive structure increases the threshold for what constitutes 'adequate' conservative trial.

Defense

Establish a WISeR neuromodulation PA template requiring: (1) conservative treatment summary with minimum 6-month trial documentation, (2) retrieval and attachment of external pain management records, (3) psychological clearance note where applicable, (4) ICD-10 diagnosis specificity (e.g., G89.29 chronic pain, M54.5x back pain with specificity). CLIP should require external records attachment field completion before PA submission transmits. For denied cases, immediately request P2P with the contractor's licensed clinician reviewer.

P2P Framing

The WISeR model specifies that final decisions must be made by a licensed clinician, not by AI screening alone. Our patient has a documented [X]-month trial of [list modalities with dates] as reflected in the attached records. CMS LCD L33788 for SCS establishes the conservative treatment standard we have met. I ask that you review the attached external records included in our submission and reconsider the denial based on the complete clinical picture rather than the structured submission fields alone.

Scenario · 03

Knee Arthroscopy PA Denied in Traditional Medicare Patient with Osteoarthritis Despite Documented Conservative Failure

Payer Argument

WISeR contractor denies PA for knee arthroscopy for a Traditional Medicare beneficiary with knee osteoarthritis, citing CMS's own evidence base that arthroscopy for OA does not improve outcomes over conservative management. Contractor argues that any arthroscopy submission for a patient with an OA ICD-10 primary diagnosis (M17.x) is presumptively non-covered under WISeR's wasteful-services reduction mandate, regardless of concurrent pathology (e.g., meniscal tear). This represents potential misapplication of the model as a blanket exclusion rather than individualized medical necessity review.

Defense

Implement ICD-10 sequencing review for all knee arthroscopy PA submissions in pilot states: if OA is present but not the surgical indication, the primary diagnosis must reflect the specific mechanical pathology (e.g., M23.201 meniscal derangement) supported by MRI report attached to submission. Surgeon must document: 'Surgical indication is [specific pathology], not osteoarthritis per se; arthroscopy for isolated OA is not the basis for this procedure.' CLIP should cross-reference ICD-10 primary code against the WISeR OA exclusion trigger and alert if M17.x leads the submission without concurrent mechanical pathology code.

P2P Framing

The WISeR model targets arthroscopy for knee osteoarthritis as a standalone indication, consistent with the evidence base. Our patient's surgical indication is [specific mechanical pathology — e.g., medial meniscal tear, confirmed on MRI dated X], for which arthroscopy remains an appropriate intervention under CMS and evidence-based guidelines. The osteoarthritis is a comorbidity, not the surgical indication. This is an individualized medical necessity determination, not a categorical exclusion case.

04 — Decision Layer

Three executive lenses

Physician Advisor

The PA's primary leverage is the model's own structural requirement: final decisions must be made by a licensed clinician, not an AI tool. In every P2P call, immediately establish the identity and specialty of the contractor's reviewing clinician and whether they had full chart access — this is a design-compliance question, not a courtesy. Anchor medical necessity to the patient's specific failure of conservative care, functional status decline, and comorbidity burden, mapped to applicable LCD criteria. Emphasize that CMMI cannot deny claims meeting existing NCD/LCD coverage standards — WISeR adds a PA gate, it does not rewrite coverage policy.

CFO / Revenue Cycle

Revenue exposure is acute and structurally novel for Traditional Medicare, which historically carried near-zero PA burden. The six pilot states represent significant Medicare FFS volume; the ~17 target outpatient services — including high-margin items like skin/tissue substitutes and nerve stimulator implants — will see denial rates that, per PSI analysis of analogous contractor models, could run 10–16× above historical baselines. Model a denial rate uplift of 15–25% on WISeR target services for FY2026 budget planning, with corresponding appeals labor cost. Most hospital PA systems are not configured to route Traditional Medicare claims through PA workflow or flag WISeR target codes.

Compliance & Legal

WISeR contractor AI tools operate under CMMI authority but are not subject to the same transparency and explainability requirements that apply to MA AI under the 2024 final rule — creating an asymmetric regulatory environment. Every WISeR denial should be logged with contractor stated criteria, licensed clinician attestation (or absence), and submitted documentation — building the administrative record for ALJ escalation and OIG audit defense. Establish a WISeR denial tracking dashboard monitoring denial rates by contractor, service category, and pilot state on a rolling 30-day basis.

05 — Denial Playbook

Documentation levers & citations

Documentation Levers

Complete clinical notes with explicit medical necessity language tied to the specific WISeR target service
Failed conservative treatment log with dates, dosages, and outcomes for each prior therapy
Relevant imaging reports, lab results, or diagnostic workup supporting the clinical indication
Licensed specialist attestation (orthopedics, pain management) where applicable
Patient functional status assessments using validated tools (Oswestry, KOOS, wound measurement grids)
Comorbidity documentation that elevates necessity or forecloses alternative treatment options

What to Cite

WISeR Model design requirement: final PA decisions must be made by licensed clinicians, not AI alone
CMMI authority boundaries: cannot override existing Medicare NCDs and LCDs
PSI report — payment-for-denials contractor models have generated denial rates up to 16× above benchmarks
42 CFR Part 405 Subpart I — Medicare Appeals procedures
CMS framing of WISeR as reducing 'unnecessary or inappropriate care'
Contractor obligation to disclose specific clinical criteria applied during AI-assisted screening

06 — Payer Impact

Projected payer behavior

PAULA watch item — projected payer behavior under this rule. Verify against current payer medical policy or provider bulletin.

Medicare FFS (Traditional Medicare)

Critical

No existing PA infrastructure for Traditional Medicare; high volume of affected procedures; contractor incentive to deny creates structural denial pressure across all six pilot states.

Medicare Advantage

Medium

Indirect policy normalization effect may trigger MA plan criteria tightening; existing PA workflows remain but benchmark denial rates may shift upward.

Commercial

Low–Medium

No immediate regulatory impact; advisory/monitoring posture warranted for future commercial PA policy shifts in the 17 procedure categories.

Medicaid FFS / MCO

Low

Speculative future risk only; current Medicaid PA frameworks are unaffected by WISeR directly.

Operationalize this brief

Get the full briefing packet, P2P scripts, and CLIP action checklist.

$149 · One-time purchase · Delivered as a downloadable executive PDF with citations and CLIP-ready operational templates.

Assess your exposure

Source: CMS Innovation Center (CMMI) — WISeR Model, effective January 1, 2026 (six-state pilot). Source Confidence: MEDIUM — Secondary policy commentary. Verify against the underlying CMS guidance before formal use.